tirzepatide after stopping Maintenance Dose Weight Loss Weight Regain After Stopping Tirzepatide:

12, 30 Aug

NICE guidance (NG28) recommends GLP-1 receptor agonists as a treatment option for adults with type 2 diabetes when: Triple therapy with metformin and two other oral drugs is not effective, not tolerated or contraindicated The person has a BMI of 35 kg/m or higher (adjust accordingly for people from particular ethnic groups) and specific psychological or other medical problems associated with obesity The person has a BMI lower than 35 kg/m and insulin would have significant occupational implications, or weight loss would benefit other significant obesity-related comorbidities GLP-1 receptor agonists may also be considered in combination with insulin therapy in specialist care settings Beyond glycaemic control, specific GLP-1 receptor agonists offer significant cardiovascular benefits

[1] [2] The severity of an overdose depends on several factors: The amount taken beyond the prescribed dose Individual patient characteristics (weight, concurrent medications) Timing of the last dose and whether other diabetes medications are being used Current blood glucose levels and recent food intake Gastrointestinal symptoms typically intensify with higher doses, as semaglutide's effect on gastric motility becomes more pronounced

and reconstitution guidance that implies human administration rather than laboratory use

Tirzepatide differs from Semaglutide because it activates both GIP and GLP-1 receptors

Semaglutide-related fatigue is often related to reduced caloric intake rather than a direct drug effect, and adjusting protein intake or meal timing can help